Avalo Therapeutics (AVTX) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Avalo Therapeutics (AVTX) over the last 11 years, with Q3 2025 value amounting to -$30.6 million.
- Avalo Therapeutics' Income towards Parent Company fell 23293.83% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year decrease of 115506.41%. This contributed to the annual value of -$35.1 million for FY2024, which is 1136.51% down from last year.
- Latest data reveals that Avalo Therapeutics reported Income towards Parent Company of -$30.6 million as of Q3 2025, which was down 23293.83% from -$20.8 million recorded in Q2 2025.
- Avalo Therapeutics' 5-year Income towards Parent Company high stood at $98.5 million for Q2 2024, and its period low was -$121.3 million during Q1 2024.
- Moreover, its 4-year median value for Income towards Parent Company was -$8.2 million (2023), whereas its average is -$8.7 million.
- Examining YoY changes over the last 5 years, Avalo Therapeutics' Income towards Parent Company showed a top increase of 130179.42% in 2024 and a maximum decrease of 111838.27% in 2024.
- Avalo Therapeutics' Income towards Parent Company (Quarter) stood at -$65000.0 in 2021, then tumbled by 12466.15% to -$8.2 million in 2023, then tumbled by 332.65% to -$35.3 million in 2024, then grew by 13.34% to -$30.6 million in 2025.
- Its last three reported values are -$30.6 million in Q3 2025, -$20.8 million for Q2 2025, and -$13.1 million during Q1 2025.